BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smart D, Jerman JC, Brough SJ, Neville WA, Jewitt F, Porter RA. The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors. Br J Pharmacol 2000;129:1289-91. [PMID: 10742282 DOI: 10.1038/sj.bjp.0703257] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nair SG, Golden SA, Shaham Y. Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats. Br J Pharmacol 2008;154:406-16. [PMID: 18223663 DOI: 10.1038/bjp.2008.3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 105] [Article Influence: 7.2] [Reference Citation Analysis]
2 Palotai M, Telegdy G, Jászberényi M. Orexin A-induced anxiety-like behavior is mediated through GABA-ergic, α- and β-adrenergic neurotransmissions in mice. Peptides 2014;57:129-34. [DOI: 10.1016/j.peptides.2014.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
3 Akbari E, Naghdi N, Motamedi F. The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides 2007;28:650-6. [PMID: 17161886 DOI: 10.1016/j.peptides.2006.11.002] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
4 Zhang JY, Nawoschik S, Kowal D, Smith D, Spangler T, Ochalski R, Schechter L, Dunlop J. Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. European Journal of Pharmacology 2003;472:33-8. [DOI: 10.1016/s0014-2999(03)01855-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
5 Kushikata T, Hirota K, Yoshida H, Kudo M, Lambert DG, Smart D, Jerman JC, Matsuki A. Orexinergic neurons and barbiturate anesthesia. Neuroscience 2003;121:855-63. [PMID: 14580935 DOI: 10.1016/s0306-4522(03)00554-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
6 de Lecea L, Sutcliffe JG, Fabre V. Hypocretins/orexins as integrators of physiological information: lessons from mutant animals. Neuropeptides 2002;36:85-95. [PMID: 12359500 DOI: 10.1054/npep.2002.0892] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
7 Blanco M, Garcı́a-caballero T, Fraga M, Gallego R, Cuevas J, Forteza J, Beiras A, Diéguez C. Cellular localization of orexin receptors in human adrenal gland, adrenocortical adenomas and pheochromocytomas. Regulatory Peptides 2002;104:161-5. [DOI: 10.1016/s0167-0115(01)00359-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
8 Taheri S, Bloom S. Orexins/hypocretins: waking up the scientific world: Orexins and hypocretins. Clinical Endocrinology 2001;54:421-9. [DOI: 10.1046/j.1365-2265.2001.01247.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
9 Rodgers R, Ishii Y, Halford J, Blundell J. Orexins and appetite regulation. Neuropeptides 2002;36:303-25. [DOI: 10.1016/s0143-4179(02)00085-9] [Cited by in Crossref: 118] [Cited by in F6Publishing: 27] [Article Influence: 5.9] [Reference Citation Analysis]
10 Katugampola S, Davenport A. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system. Trends in Pharmacological Sciences 2003;24:30-5. [DOI: 10.1016/s0165-6147(02)00007-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
11 Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity--a review. Neuropeptides 2006;40:375-401. [PMID: 16935329 DOI: 10.1016/j.npep.2006.07.001] [Cited by in Crossref: 285] [Cited by in F6Publishing: 250] [Article Influence: 17.8] [Reference Citation Analysis]
12 Calu DJ, Chen YW, Kawa AB, Nair SG, Shaham Y. The use of the reinstatement model to study relapse to palatable food seeking during dieting. Neuropharmacology 2014;76 Pt B:395-406. [PMID: 23660229 DOI: 10.1016/j.neuropharm.2013.04.030] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
13 Haynes AC, Chapman H, Taylor C, Moore GB, Cawthorne MA, Tadayyon M, Clapham JC, Arch JR. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regulatory Peptides 2002;104:153-9. [DOI: 10.1016/s0167-0115(01)00358-5] [Cited by in Crossref: 97] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
14 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
15 Imperatore R, Cristino L. Role of Orexin-B/Orexin 2 receptor in myocardial protection. Clinical Science 2019;133:853-7. [DOI: 10.1042/cs20181036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Akbari E, Motamedi F, Naghdi N, Noorbakhshnia M. The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task. Behav Brain Res 2008;187:172-7. [PMID: 17977608 DOI: 10.1016/j.bbr.2007.09.019] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 4.0] [Reference Citation Analysis]
17 Volkoff H, Peter RE. Interactions between orexin A, NPY and galanin in the control of food intake of the goldfish, Carassius auratus. Regulatory Peptides 2001;101:59-72. [DOI: 10.1016/s0167-0115(01)00261-0] [Cited by in Crossref: 94] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
18 van den Top M, Nolan MF, Lee K, Richardson PJ, Buijs RM, Davies CH, Spanswick D. Orexins induce increased excitability and synchronisation of rat sympathetic preganglionic neurones. J Physiol. 2003;549:809-821. [PMID: 12702746 DOI: 10.1113/jphysiol.2002.033290] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 4.1] [Reference Citation Analysis]
19 Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001;18:78-105. [PMID: 11435802 DOI: 10.1097/00004691-200103000-00002] [Cited by in Crossref: 217] [Cited by in F6Publishing: 164] [Article Influence: 10.3] [Reference Citation Analysis]
20 Hervieu G, Cluderay J, Harrison D, Roberts J, Leslie R. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 2001;103:777-97. [DOI: 10.1016/s0306-4522(01)00033-1] [Cited by in Crossref: 340] [Cited by in F6Publishing: 109] [Article Influence: 16.2] [Reference Citation Analysis]
21 Meneguetti BT, Cardoso MH, Ribeiro CF, Felício MR, Pinto IB, Santos NC, Carvalho CM, Franco OL. Neuropeptide receptors as potential pharmacological targets for obesity. Pharmacology & Therapeutics 2019;196:59-78. [DOI: 10.1016/j.pharmthera.2018.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
22 Voisin T, Firar AE, Avondo V, Laburthe M. Orexin-induced apoptosis: the key role of the seven-transmembrane domain orexin type 2 receptor. Endocrinology 2006;147:4977-84. [PMID: 16857748 DOI: 10.1210/en.2006-0201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
23 Smart D, Haynes AC, Williams G, Arch JR. Orexins and the treatment of obesity. Eur J Pharmacol 2002;440:199-212. [PMID: 12007536 DOI: 10.1016/s0014-2999(02)01429-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
24 Imperatore R, Palomba L, Cristino L. Role of Orexin-A in Hypertension and Obesity. Curr Hypertens Rep 2017;19. [DOI: 10.1007/s11906-017-0729-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
25 Wang B, You ZB, Wise RA. Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network. Biol Psychiatry 2009;65:857-62. [PMID: 19251246 DOI: 10.1016/j.biopsych.2009.01.018] [Cited by in Crossref: 87] [Cited by in F6Publishing: 94] [Article Influence: 6.7] [Reference Citation Analysis]
26 Zhang Y, Kowal D, Kramer A, Dunlop J. Evaluation of FLIPR Calcium 3 Assay Kit—A New No-Wash Fluorescence Calcium Indicator Reagent. J Biomol Screen 2003;8:571-7. [DOI: 10.1177/1087057103257240] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
27 Kukkonen JP, Holmqvist T, Ammoun S, Åkerman KEO. Functions of the orexinergic/hypocretinergic system. American Journal of Physiology-Cell Physiology 2002;283:C1567-91. [DOI: 10.1152/ajpcell.00055.2002] [Cited by in Crossref: 200] [Cited by in F6Publishing: 188] [Article Influence: 10.0] [Reference Citation Analysis]
28 Palotai M, Telegdy G, Ekwerike A, Jászberényi M. The action of orexin B on passive avoidance learning. Involvement of neurotransmitters. Behav Brain Res 2014;272:1-7. [PMID: 24931796 DOI: 10.1016/j.bbr.2014.06.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
29 Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, Jerman JC. SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol 2001;132:1179-82. [PMID: 11250867 DOI: 10.1038/sj.bjp.0703953] [Cited by in Crossref: 223] [Cited by in F6Publishing: 226] [Article Influence: 10.6] [Reference Citation Analysis]
30 Rasmussen K, Hsu MA, Yang Y. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. Neuropsychopharmacology 2007;32:786-92. [PMID: 17063151 DOI: 10.1038/sj.npp.1301239] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
31 Shahid IZ, Rahman AA, Pilowsky PM. Orexin and Central Regulation of Cardiorespiratory System. Sleep Hormones. Elsevier; 2012. pp. 159-84. [DOI: 10.1016/b978-0-12-394623-2.00009-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
32 Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Prog Brain Res 2012;198:163-88. [PMID: 22813974 DOI: 10.1016/B978-0-444-59489-1.00010-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 7.1] [Reference Citation Analysis]
33 Voisin T, Firar AE, Rouyer‐fessard C, Gratio V, Laburthe M. A hallmark of immunoreceptor, the tyrosine‐based inhibitory motif ITIM, is present in the G protein‐coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism. FASEB j 2008;22:1993-2002. [DOI: 10.1096/fj.07-098723] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
34 Kilduff TS, Peyron C. The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders. Trends in Neurosciences 2000;23:359-65. [DOI: 10.1016/s0166-2236(00)01594-0] [Cited by in Crossref: 306] [Cited by in F6Publishing: 83] [Article Influence: 13.9] [Reference Citation Analysis]
35 Smart D, Jerman JC. The physiology and pharmacology of the orexins. Pharmacology & Therapeutics 2002;94:51-61. [DOI: 10.1016/s0163-7258(02)00171-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
36 Li TL, Chen JYS, Huang SC, Dai YE, Hwang LL. Cardiovascular pressor effects of orexins in the dorsomedial hypothalamus. Eur J Pharmacol 2018;818:343-50. [PMID: 29104046 DOI: 10.1016/j.ejphar.2017.11.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
37 Zhou L, Sun WL, See RE. Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction. Pharmaceuticals (Basel) 2011;4:804-21. [PMID: 23997653 DOI: 10.3390/ph4060804] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
38 Moreno G, Perelló M, Gaillard RC, Spinedi E. Orexin a stimulates hypothalamic-pituitary-adrenal (HPA) axis function, but not food intake, in the absence of full hypothalamic NPY-ergic activity. Endocrine 2005;26:99-106. [PMID: 15888921 DOI: 10.1385/ENDO:26:2:099] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
39 Russell SH, Small CJ, Dakin CL, Abbott CR, Morgan DGA, Ghatei MA, Bloom SR. The Central Effects of Orexin-A in the Hypothalamic-Pituitary-Adrenal Axis In Vivo and In Vitro in Male Rats: Effects of central orexin-A on CRF, ACTH and corticosterone release. Journal of Neuroendocrinology 2001;13:561-6. [DOI: 10.1046/j.1365-2826.2001.00672.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 4.1] [Reference Citation Analysis]
40 Zhou L, Smith RJ, Do PH, Aston-Jones G, See RE. Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats. Neuropharmacology 2012;63:1201-7. [PMID: 22971541 DOI: 10.1016/j.neuropharm.2012.07.044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
41 Arch J. Orexins, feeding and the big picture. Br J Nutr 2000;84:401-3. [DOI: 10.1017/s0007114500001707] [Cited by in Crossref: 16] [Article Influence: 1.1] [Reference Citation Analysis]
42 Fan Y, Jiang E, Hahka T, Chen QH, Yan J, Shan Z. Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats. Acta Physiol (Oxf) 2018;222. [PMID: 28872777 DOI: 10.1111/apha.12963] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
43 Kukkonen JP, Åkerman KEO. Intracellular Signal Pathways Utilized by the Hypocretin/Orexin Receptors. In: de Lecea L, Sutcliffe JG, editors. Hypocretins. Boston: Springer US; 2005. pp. 221-31. [DOI: 10.1007/0-387-25446-3_14] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]